Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash from Financing Activities (2016 - 2026)

Aytu Biopharma has reported Cash from Financing Activities over the past 15 years, most recently at -$6.3 million for Q4 2025.

  • Quarterly Cash from Financing Activities fell 126.92% to -$6.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.3 million through Dec 2025, up 5408.76% year-over-year, with the annual reading at $15.4 million for FY2025, 1323.69% up from the prior year.
  • Cash from Financing Activities was -$6.3 million for Q4 2025 at Aytu Biopharma, down from $2.3 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $13.6 million in Q3 2022 and troughed at -$6.3 million in Q4 2025.
  • The 5-year median for Cash from Financing Activities is $911000.0 (2024), against an average of $1.7 million.
  • Year-over-year, Cash from Financing Activities plummeted 2090.48% in 2024 and then surged 1116.57% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $6.6 million in 2021, then tumbled by 128.3% to -$1.9 million in 2022, then soared by 93.24% to -$126000.0 in 2023, then plummeted by 2090.48% to -$2.8 million in 2024, then crashed by 126.92% to -$6.3 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Cash from Financing Activities are -$6.3 million (Q4 2025), $2.3 million (Q3 2025), and $13.0 million (Q2 2025).